DE

507.9

+0.88%↑

FDX

228.73

-0.96%↓

PAYX

142.23

+0.99%↑

FAST

45.57

+0.95%↑

CPRT

45.93

-0.02%↓

DE

507.9

+0.88%↑

FDX

228.73

-0.96%↓

PAYX

142.23

+0.99%↑

FAST

45.57

+0.95%↑

CPRT

45.93

-0.02%↓

DE

507.9

+0.88%↑

FDX

228.73

-0.96%↓

PAYX

142.23

+0.99%↑

FAST

45.57

+0.95%↑

CPRT

45.93

-0.02%↓

DE

507.9

+0.88%↑

FDX

228.73

-0.96%↓

PAYX

142.23

+0.99%↑

FAST

45.57

+0.95%↑

CPRT

45.93

-0.02%↓

DE

507.9

+0.88%↑

FDX

228.73

-0.96%↓

PAYX

142.23

+0.99%↑

FAST

45.57

+0.95%↑

CPRT

45.93

-0.02%↓

Search

Ocugen Inc

Geschlossen

1.05 -1.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.02

Max

1.08

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.5M

-15M

Verkäufe

717K

1.5M

Gewinnspanne

-1,036.462

Angestellte

95

EBITDA

-350K

-14M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+491.59% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

120M

324M

Vorheriger Eröffnungskurs

2.92

Vorheriger Schlusskurs

1.05

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Ocugen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juli 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15. Juli 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15. Juli 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15. Juli 2025, 20:07 UTC

Ergebnisse

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15. Juli 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15. Juli 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15. Juli 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15. Juli 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15. Juli 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15. Juli 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15. Juli 2025, 18:32 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15. Juli 2025, 18:31 UTC

Akquisitionen, Fusionen, Übernahmen

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15. Juli 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15. Juli 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juli 2025, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15. Juli 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15. Juli 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. Juli 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Peer-Vergleich

Kursveränderung

Ocugen Inc Prognose

Kursziel

By TipRanks

491.59% Vorteil

12-Monats-Prognose

Durchschnitt 6.33 USD  491.59%

Hoch 8 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocugen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.6818 / 0.74Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

No Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.